Over the past three months, Indian equities have been highly volatile, but the turbulence has been accompanied by a strong upward drift. The benchmark BSE Sensex gained about 4%, while the broader market quietly outperformed by a much wider margin.

The real action unfolded across the wider universe, where the BSE 500 surged nearly 10%, driven by persistent buying interest across large and midcap stocks. Momentum steadily built beneath the surface, even as the headline indices posted more modest gains.

In this rally, market breadth told the real story: around 32 stocks gained more than 50% in just three months. Among them, 13 standout performers delivered returns ranging from 70% to 200%, including three multibaggers that more than doubled investor wealth in a remarkably short span. What appeared to be a routine market phase on the surface turned into a significant wealth-creation opportunity for investors positioned in the right segments of the market.

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

EasyJet has rejected a fourth takeover offer worth £4.93bn from Castlelake.

The low-cost Luton-based airline said the US investment firm’s bid was worth £6.50 a share, compared with the previous offers of £5.60, £6 and £6.25 a share.

A spokesperson said it was giving Castlelake until 17:00 BST on 5 July to make a firm offer or walk away.

“Having carefully reviewed it with its advisers, the board of EasyJet continues to regard the fourth proposal as substantially undervaluing the company and its prospects and continuing to give rise to significant questions of deliverability,” said EasyJet.

EasyJet said the takeover interest came at a time when its share price had been pushed down by concerns about the consequences of the Iran war.

The FTSE 250 firm’s shares had dropped by about 30% over the past year, before news of Castlelake’s interest.

EasyJet said it remained “concerned” about Castlelake’s ownership structure and ability to deliver any offer, adding the investor would need to provide “satisfactory assurances and commitments” on those issues.

Castlelake has assets under management worth $36bn (£27.3bn).

Under the deal, EasyJet would be 49% owned by Castlelake and co-investors including Brookfield Asset Management, and 51% owned by individual European Union investors.

Do you have a story suggestion for Beds, Herts or Bucks? Contact us below.

The amount of money owed to energy suppliers by customers has risen again to a new record high of £4.79bn.

Regulator Ofgem said that total debt and arrears in England, Wales and Scotland had risen by 15% in a year.

The data, external is updated every three months, with the newly-published figures covering the period from January to the end of March. They relate to energy customers who have been in debt for more than three months.

Average arrears for those without a repayment plan hit £1,876 for electricity and £1,623 for gas – more than twice the amount as those who have a repayment agreement.

Energy prices will rise for millions of households in July – driven by the increase in the cost of gas.

Experts say there are options to cut bills, even though people may feel they have already made every saving possible.

AbbVie Inc. shares closed virtually unchanged on Wednesday, finishing at $234.89 after a modest gain of $0.13, as investors assessed the company’s position in a competitive pharmaceutical landscape marked by patent expirations and pipeline developments.

The stability in trading reflected continued confidence in AbbVie’s core immunology franchise, particularly its flagship product Humira’s successors and growing oncology portfolio. The biopharmaceutical company has navigated the loss of exclusivity for its biggest product through strategic diversification and acquisitions.

AbbVie’s performance demonstrates resilience in a sector facing pricing pressures, regulatory scrutiny and competition from biosimilars. Its focus on specialty medicines and innovative therapies has supported revenue stability despite challenges in its legacy portfolio.

The company continues investing heavily in research and development, with emphasis on advancing treatments for autoimmune diseases, cancer and neurological disorders. Recent data readouts and regulatory milestones have generated interest among analysts and investors.

Key Product Performance

Humira, once the world’s best-selling drug, continues facing biosimilar competition, but AbbVie has successfully transitioned patients to newer immunology assets like Skyrizi and Rinvoq. These products have shown strong uptake and expanded indications, helping offset revenue declines.

Oncology remains a growth driver, with medicines like Imbruvica and Venclexta maintaining significant market presence. Pipeline candidates in solid tumors and blood cancers could provide additional catalysts in coming years.

Aesthetics and eye care products, including Botox and Restasis, contribute diversified revenue streams less exposed to patent cliffs. These consumer-facing businesses provide stability amid volatility in specialty pharmaceuticals.

Strategic Initiatives

AbbVie’s acquisition strategy has played a key role in portfolio renewal. Strategic purchases have bolstered capabilities in targeted therapy areas and expanded its global footprint.

The company maintains a disciplined approach to capital allocation, balancing R&D investment with shareholder returns through dividends and buybacks. Its strong cash flow generation supports these priorities.

Digital transformation and data analytics initiatives aim to enhance clinical development efficiency and commercial execution. These efforts position AbbVie to compete effectively in an increasingly technology-driven healthcare environment.

Industry Challenges

The pharmaceutical sector faces ongoing pressures from drug pricing debates, patent expirations and regulatory requirements. AbbVie’s experience navigating the Humira transition provides lessons for managing future losses of exclusivity.

Biosimilar competition has intensified, requiring innovative defense strategies and lifecycle management. Companies with robust pipelines and diversified portfolios are better positioned to weather these cycles.

Global healthcare spending trends, reimbursement policies and demographic shifts influence demand for AbbVie’s products. Aging populations in developed markets support long-term growth in chronic disease treatments.

Investment Outlook

AbbVie attracts investors seeking dividend growth and exposure to innovative medicines. Its yield and history of increases appeal to income-focused portfolios.

Valuation metrics reflect expectations for pipeline success and margin management. Risks include clinical trial outcomes, regulatory decisions and competitive dynamics.

Longer-term prospects remain positive given AbbVie’s established franchises and development programs. Successful commercialization of new therapies could drive renewed growth.

Analysts monitor upcoming clinical data and regulatory milestones closely. Execution on commercial strategies for key products will influence financial performance.

Research and Development Focus

AbbVie’s pipeline spans multiple therapeutic areas with several candidates in late-stage development. Advances in immunology, oncology and neuroscience could yield significant new treatments.

Collaboration with academic institutions and biotechnology companies expands innovation reach. These partnerships accelerate discovery while sharing development risks.

Precision medicine approaches and biomarker-driven therapies represent growing areas of emphasis. Such strategies aim to improve efficacy and safety profiles for patients.

Investment levels in R&D remain substantial, reflecting commitment to long-term value creation. Balancing near-term financial targets with pipeline investment requires careful management.

Corporate Responsibility and Sustainability

AbbVie engages in initiatives addressing healthcare access, diversity and environmental impact. These efforts enhance reputation and align with stakeholder expectations.

Patient assistance programs and global health partnerships demonstrate commitment beyond commercial activities. Such initiatives support brand value and talent attraction.

Sustainability reporting covers environmental footprint, supply chain practices and governance standards. Transparency in these areas has become increasingly important for investors.

Outlook

AbbVie’s recent share price performance reflects typical market dynamics in the healthcare sector. The company’s strategic direction and execution capabilities will determine its ability to deliver sustained growth.

Upcoming catalysts include clinical trial results, regulatory decisions and commercial updates. Management will continue balancing innovation investment with financial discipline.

The pharmaceutical industry’s evolution toward personalized medicine and advanced therapies creates opportunities for established players like AbbVie. Its strong foundation in immunology and expanding oncology presence position it favorably.

As the company navigates patent landscapes and competitive pressures, focus remains on delivering value for patients and shareholders. AbbVie’s track record suggests capability to adapt and thrive in changing healthcare environments.